TP53 and cancer: These converging lines of evidence reveal that tNOX expression and the ultimate cellular response toward oxaliplatin differ markedly in cells with or without functional p53, further suggesting that targeting of tNOX could be an alternative therapeutic strategy in p53-inactivated cancer scenarios.